Evolving biotech to tech powerhouses

Bioscientists aren’t technologists. Scientists are brilliant, but integrating tech—like connecting applications or streamlining lab equipment digitally—isn’t their specialty. Yet, companies heavily lean on their scientists to handle most of this.

Here’s the thing: with the right tech integration, R&D could move faster and patent-driven revenues could last longer - Both industry and society stand to gain from this increase in productivity.

In the last decade, biotech has seen a push toward tech-integration. Companies that fully embrace this are called “Techbio” companies—biotech firms that lean into technology to do more, faster. This is paying off. These Techbio companies are cutting drug development times in half, aiming for 4-6 years instead of the traditional 8-12 year timelines. The result is a better ROI and an more predictable path to market.

Right now, traditional biotechs face some serious challenges: shrinking profits, high R&D costs, and a shortage of skilled scientists. To stay competitive, they need to embrace tech integration. Done right, this approach can reduce development time and boost patent life.

This enables:

1. More affordable drugs.

2. Higher profits for innovative companies pushing boundaries.

3. Innovative business cases for smaller patient populations.

4. Moonshots for completely novel therapies and treatments.

Aradon helps biotech companies make that leap—enabling scientists to evolve their biotech organisations to technology powerhouses.